68P Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study

{"title":"68P Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study","authors":"A. Soria Rivas , M.A. Berciano Guerrero , E. Muñoz-Couselo , P.C. Cerezuela-Fuentes , C. Aguado , P. Ayala de Miguel , G. Crespo Herrero , L. Gutierrez Sanz , L. Ostios Garcia , D. Vilanova Larena , S. Martin Algarra , I. Marquez-Rodas","doi":"10.1016/j.iotech.2024.100811","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100811"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immuno-oncology technology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590018824001084","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}